Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related DSW
5 Apparel Pair Trades To Try In 2016
5 Cybersecurity Fails That Put Customers At Risk
Strong read from NPD on athletic footwear amid social fitness trend (Seeking Alpha)
Related PFE
How To Invest In An Aging World With The 'Live Long & Prosper' ETF
RBC Analyst Says 'Buy The Spread' On Allergan-Pfizer Deal
Pfizer To Reorganize After Allergan Buyout, With Saunders President (Investor's Business Daily)

Analysts at Sterne Agee downgraded DSW (NYSE: DSW) from Neutral to Underperform. The target price for DSW is set to $23. DSW's shares closed at $27.16 on Friday.

BMO Capital downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform. The target price for Pfizer has been lowered from $34 to $31. Pfizer's shares closed at $30.19 on Friday.

Analysts at Canaccord Genuity downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Buy to Hold. The target price for AcelRx Pharmaceuticals has been lowered from $16.00 to $8.00. AcelRx Pharmaceuticals' shares closed at $10.83 on Friday.

Deutsche Bank downgraded Lear (NYSE: LEA) from Buy to Hold. The target price for Lear has been raised from $100.00 to $103.00. Lear's shares closed at $99.00 on Friday.

Latest Ratings for DSW

DateFirmActionFromTo
Nov 2015Credit SuisseMaintainsOutperform
Nov 2015Wells FargoInitiates Coverage onUnderperform
Nov 2015Telsey Advisory GroupDowngradesOutperformMarket Perform

View More Analyst Ratings for DSW
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (DSW + ACRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters